SignatureFD’s Ocular Therapeutix OCUL Stock Holding History

SignatureFD’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$844	Buy	+110	New	+$1.08K	﹤0.01%	3352
2026 Q2	–	Sell	-341	Closed	-$2.89K	–	3595
2026 Q1	$2.89K	Buy	+341	New	+$3.25K	﹤0.01%	2951
2025 Q2	–	Sell	-781	Closed	-$5.72K	–	3377
2025 Q1	$5.72K	Buy	+781	New	+$6K	﹤0.01%	2552
2024 Q2	–	Sell	-76	Closed	-$692	–	3216
2024 Q1	$692	Buy	+76	New	+$539	﹤0.01%	2990
2023 Q2	–	Sell	-192	Closed	-$1.01K	–	3326
2023 Q1	$1.01K	Buy	+192	New	+$912	﹤0.01%	2991
2022 Q4	–	Sell	-1,195	Closed	-$5K	–	3376
2022 Q3	$5K	Buy	+1,195	New	+$6.02K	﹤0.01%	2447
2021 Q4	–	Sell	-134	Closed	-$1K	–	3218
2021 Q3	$1K	Hold	134	–	–	﹤0.01%	2875
2021 Q2	$2K	Hold	134	–	–	﹤0.01%	2605
2021 Q1	$2K	Hold	134	–	–	﹤0.01%	2508
2020 Q4	$3K	Hold	134	–	–	﹤0.01%	2159
2020 Q3	$1K	Buy	+134	New	+$1.11K	﹤0.01%	2467

Other funds holding OCUL

Summer Road West Palm Beach, Florida $135M AUM 15.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deltec Asset Management New York $642M AUM 16.66% 1-Year Est. Return

Empire Life Investments Toronto, Ontario, Canada $1.83B AUM 33.18% 1-Year Est. Return

IMC Chicago Chicago, Illinois $483B AUM 41.26% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return

SignatureFD's OCUL Position: Q3 2026 in Review

SignatureFD opened a new position in Ocular Therapeutix (OCUL) in Q3 2026: 110 shares worth $844. The stake represents ﹤0.01% of the portfolio and ranks #3352 among its holdings. This is a return to the name: SignatureFD previously reported a position in OCUL as recently as Q1 2026.

SignatureFD first reported a position in OCUL in Q3 2020 and has held it in 11 quarters since. The position peaked at $5.72K in Q1 2025. 91 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.

SignatureFD held 110 shares of Ocular Therapeutix worth $844 as of Q3 2026.
Ocular Therapeutix was a new SignatureFD position in Q3 2026.
Ocular Therapeutix made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #3352 holding.
SignatureFD first reported a position in Ocular Therapeutix in Q3 2020 and has held it in 11 quarters since.
SignatureFD's Ocular Therapeutix position peaked at $5.72K in Q1 2025.
91 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.